Bayer Web site promotes 12,000-patient aspirin clinical trial

Bayer Web site promotes 12,000-patient aspirin clinical trial

 

Bayer has launched a Web site to educate researchers and clinicians about one of the largest-ever clinical studies conducted in a population at moderate risk of initial cardiovascular disease events. Bayer's ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial will study use of aspirin for primary prevention of events associated with cardiovascular disease. According to the site, www.Arrive-study.com, the trial will study about 12,000 patients at 400 study sites in five countries: Germany, Italy, Spain, the United Kingdom, and the United States. The site includes information about the trial and eligibility criteria and also about aspirin and cardiovascular disease. In addition, there are ARRIVE resources such as links, conference slides, and video of key opinion leaders and discussion from the 2007 ARRIVE Symposium.